Coronavirus research

How type 1 interferon deficiency hints at severe forms of COVID-19

Which patient will develop a severe form of COVID-19? This is an essential question which must be answered in order to improve the individual management and the prognosis of these patients.

In a publication in the journal Science, teams from the Assistance publique – Hôpitaux de Paris (AP-HP), Inserm, Université de Paris, Institut Pasteur and Institut Imagine describe a unique and unexpected immunological phenotype in severe and critical patients, consisting of a severely impaired type I interferon (IFN) response, associated with persistent blood viral load and an excessive inflammatory response.

About 5% of people with COVID-19 progress to a severe or critical form, including severe pneumonia, which turns into acute respiratory distress syndrome (ARDS). These forms sometimes occur at the beginning of the disease, clinical observations generally describe its progression in two stages, starting with a mild to moderate form, followed by respiratory worsening 9 to 12 days after the appearance of the first symptoms. This sudden development suggests a deregulation of the host's inflammatory response. A growing body of evidence suggests that this worsening is caused by a sharp increase in cytokines. This runaway inflammatory response is correlated with massive infiltration into the lungs of innate immune cells, namely neutrophils and monocytes, creating lung damage and ARDS.

Recommended article

Photo

Deadly mechanism uncovered

Inside COVID-19's 'cytokine storm'

Leading immunologists in Japan are proposing a possible molecular mechanism that causes massive release of proinflammatory cytokines, or a cytokine storm, leading to the acute respiratory distress syndrome (ARDS) in COVID-19 patients. Their suggestions, published in the journal Immunity, are based on recent findings that explain how SARS-CoV-2 enters human cells.

Because of similarities to a genetic disease leading to a comparable pulmonary pathology, researchers initially assumed an excessive production of IFN, a marker response to infections. However in seriously ill patients, the teams show that both production and activity of type I IFNs are greatly reduced in the most severe forms of COVID-19. Added to this is a persistent viral load in the blood, testifying to the poor control of viral replication by the immune system of patients and leading to the runaway of an ineffective and pathological inflammatory response. Inflammation, caused by the transcription factor NF-kB, also leads to an increase in the production and signaling of tumor necrosis factor (TNF) -alpha and interleukin IL-6, a pro-inflammatory cytokine.

Recommended article

Photo

Coping with Covid-19

How France handles the coronavirus pandemic

The first case of the new coronavirus infection was reported on the 24th January. As of 22nd March 2020, there are 14 459 confirmed cases of Covid-19 in France with 562 deaths, as the disease is in an exponential phase these figures will have multiplied several fold by the time this article is published. The strategy taken by the French to stem the spread of the virus and relieve the pressure on…

This weak signature of type I IFN differs from the response induced by other respiratory viruses such as human syncitial respiratory virus or influenza A virus, both of which are characterized by high production of type I IFN.

The study also reveals that low levels of IFN type 1 in plasma precede the clinical worsening of patients and their transfer to intensive care. Circulating IFN type 1 levels could be used to stage of the disease, with the lowest levels seen in the most severe patients. These results suggest that in SARS-CoV-2 infection, the production of type I IFN is slowed down in the infected host, which could explain the more frequent severe forms in individuals with low production of this cytokine, such as the elderly or those with co-morbidities. Therefore, type I IFN deficiency could be a signature of severe forms of COVID-19 and could help identify a high-risk population.

These results further suggest that administration of IFN-alpha in combination with anti-inflammatory therapy targeting IL-6 or TNF-α, or corticosteroids such as dexamethasone, in the most severe patients may be a possible therapeutic pathway to stop severe forms of COVID-19.


Source: Université de Paris

16.07.2020

Read all latest stories

Related articles

Photo

Coronavirus vaccine research

'Immune memory' of blood stem cells could help fight COVID-19

Blood stem cells have a surprising ability. In addition to ensuring the continuous renewal of blood cells, they keep track of past infections so that faster and more effective immune responses can be…

Photo

Coronavirus research

Boosting the immune system: a potential treatment strategy for COVID-19?

As the COVID-19 pandemic continues to claim lives around the world, much research has focused on the immune system’s role in patients who become seriously ill. A popular theory has it that the…

Photo

Re-evaluation of the coronavirus disease

COVID-19: A tale of two conditions

The SARS CoV-2 virus which causes COVID-19 may have been named prematurely. As more has become known about the infection, the severe disease does not appear to be a respiratory syndrome at all.…

Related products

AB Medical – V-Tube EDTA K2, K3

Blood Cell Counter

AB Medical – V-Tube EDTA K2, K3

AB Medical V-Tube
Analyticon Biotechnologogies – Hemolyzer 3 NG / Hemolyzer 5 NG

Blood Cell Counter

Analyticon Biotechnologogies – Hemolyzer 3 NG / Hemolyzer 5 NG

Analyticon Biotechnologies AG
BD Vacutainer UltraTouch Push Button Blood Collection Set

Blood Collection

BD Vacutainer UltraTouch Push Button Blood Collection Set

BD – Becton Dickinson
Beckman Coulter – Access 25(OH) Vitamin D Total

Immunoassays

Beckman Coulter – Access 25(OH) Vitamin D Total

Beckman Coulter, Inc.
Beckman Coulter – Access Active B12

Immunoassays

Beckman Coulter – Access Active B12

Beckman Coulter, Inc.